Login
Register
Submit a Paper
Propose a Special lssue
Open Access
RESIDENT’S CORNER
BCG pyelonephritis following intravesical therapy for transitional cell carcinoma
Department of Urology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA
Address correspondence to Dr. David D. Thiel, Mayo Clinic
Jacksonville, 3 East Urology, 4500 San Pablo Road,
Jacksonville, Florida 32224 USA
Canadian Journal of Urology 2007, 14(2), 3523-3525.
Download PDFAbstract
Bacillus Calmette-Guerin (BCG) is a common intravesical agent utilized for superficial transitional cell carcinoma of the bladder. The potential for side effects and complications does exist secondary to the utilization of live attenuated bacteria. We present the case of a 70- year old male that developed BCG pyelonephritis and associated renal mass following the fifth of six weekly intravesical BCG therapies. The patient improved clinically and renal mass resolved following 3 months of isoniazid monotherapy without renal biopsy.Keywords
bladder neoplasm, BCG, intravesical therapy
Cite This Article
APA Style
Garcia, J.E., Thiel, D.D., Broderick, G.A. (2007). BCG pyelonephritis following intravesical therapy for transitional cell carcinoma. Canadian Journal of Urology, 14(2), 3523–3525.
Vancouver Style
Garcia JE, Thiel DD, Broderick GA. BCG pyelonephritis following intravesical therapy for transitional cell carcinoma. Can J Urology. 2007;14(2):3523–3525.
IEEE Style
J.E. Garcia, D.D. Thiel, and G.A. Broderick, “BCG pyelonephritis following intravesical therapy for transitional cell carcinoma,” Can. J. Urology, vol. 14, no. 2, pp. 3523–3525, 2007.
Copyright © 2007 The Author(s). Published by Tech Science Press.This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Downloads
Citation Tools
